Developing a Successful HIV Vaccine.
Baltimore, United States. In J Infect Dis, 15 Aug 2015
Immunogens targeting gp120 have been developed that block infection in monkeys and mimic the modest success of the RV144 clinical trial in that protection is short-lived following a decline in antibody-depending cell-mediated cytotoxicity-like antibodies.
Prospects for a globally effective HIV-1 vaccine.
Bethesda, United States. In Vaccine, 19 Jul 2015
A correlates analysis compared vaccine-induced immune responses in vaccinated-infected and vaccinated-uninfected volunteers suggested that IgG specific for the V1V2 region of gp120 was associated with reduced risk of HIV-1 infection and that plasma Env IgA was directly correlated with infection risk.
Recent strategies targeting HIV glycans in vaccine design.
Waltham, United States. In Nat Chem Biol, Dec 2014
These antibodies bind conserved vulnerable sites on the viral envelope glycoprotein gp120, and identification of these sites has provided exciting clues about the design of potentially effective vaccines.
Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
Bethesda, United States. In Nature, Nov 2014
The human immunodeficiency virus type 1 (HIV-1) envelope (Env) spike, comprising three gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by rearranging from a mature unliganded state, through receptor-bound intermediates, to a post-fusion state.